Aimovig (erenumab)
- Region
- 🇪🇺 EU
- Active substance
- erenumab
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Migraine Disorders
- CHMP opinion
- Fri 01 Jun 2018
- EU approval
- Thu 26 Jul 2018
- Application
- EMEA/H/C/004447
- ATC
- N02CD01
- Official record
- www.ema.europa.eu
Indication
Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.
Regulatory milestones
No milestones recorded in the last year.
Follow Aimovig
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.